Your browser doesn't support javascript.
In high-risk inpatients with COVID-19, therapeutic- vs. standard-dose heparin reduced thromboembolism or death at 30 d.
Bikdeli, Behnood; Garcia, David A.
  • Bikdeli B; Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA (B.B.).
  • Garcia DA; University of Washington, Seattle, Washington, USA (D.A.G.).
Ann Intern Med ; 175(2): JC17, 2022 02.
Article in English | MEDLINE | ID: covidwho-1716078
ABSTRACT
SOURCE CITATION Spyropoulos AC, Goldin M, Giannis D, et al. Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19 the HEP-COVID randomized clinical trial. JAMA Intern Med. 2021;1811612-20. 34617959.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Venous Thromboembolism / COVID-19 Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Ann Intern Med Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Venous Thromboembolism / COVID-19 Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Ann Intern Med Year: 2022 Document Type: Article